Among the varied provisions in the voluminous Patient Protection and Affordable Care Act, a/k/a the Health Care Reform Bill, Congress has appropriated up to $1 billion in tax credits and grants to defray the costs of therapeutic research by small and mid-size life sciences companies. Beneficial even for companies without income tax liability, these incentives will soon be awarded in an application process that is sure to be highly competitive.